3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Venous Thromboembolism
1
TP53 Y220C Mutation
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Pulmonary Embolism
1
Prostatic Neoplasms, Castration-Resistant
1
Peripheral Nervous System Diseases
1
Neoplasms
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Healthy Participants
1
Healthy Adult Participants
1
Endometrial Neoplasms
1
Drug-drug Interaction,SHR3680
1
Cardiotoxicity
1
Breast Neoplasms
1
Advanced Solid Malignancies
1
Interventions
Doxorubicin
6
Specimen Handling
5
Radiotherapy
3
Radiation
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Biopsy
3
pembrolizumab
2
liposomal doxorubicin
2
eribulin
2
Ifosfamide
2
toripalimab
1
talimogene laherparepvec
1
rucaparib
1
ribociclib
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
olaparib
1
lenvatinib
1
futibatinib
1
durvalumab
1
dinutuximab
1
cemiplimab
1
cediranib
1
cabozantinib
1
avelumab
1
anlotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leiomyosarcoma
×
Rosuvastatin Calcium
×
1 year
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled